Citigroup Inc Eliem Therapeutics, Inc. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 329,548 shares of ELYM stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
329,548
Previous 1,611,887
79.56%
Holding current value
$1.35 Million
Previous $6.62 Million
79.56%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ELYM
# of Institutions
68Shares Held
49.1MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2.5MShares$10.3 Million0.01% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.32MShares$5.41 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.15% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...